Navigation Links
Discovery of an anti-inflammatory substance
Date:11/8/2010

This release is available in German.

The messenger interleukin-27 plays an important role when the human body blocks inflammations. This was discovered by an international research team, of which the Kiel Professors Joachim Grtzinger and Stefan Rose-John, as well as the doctoral candidate, Bjrn Spudy, are a part of. The research findings of the scientists from Kiel, the US and Great Britain were published yesterday, Sunday (7 November 2010), in the online advance edition of Nature Immunology.

The human immune system reacts to bodily injuries and infections with inflammation. This is important for the healing process, but can result in harmful effects if it becomes chronic. Inflammation is triggered by messengers such as the cytokine interleukin-6 (IL-6). This peptide hormone latches on to special receptor molecules on cells and compels inflammation. "We observed that another cytokine, interleukin-27, can counteract this effect", explained Professor Joachim Grtzinger, from the Institute of Biochemistry at Kiel University. "IL-27 latches on to the same receptors as IL-6 and thus inhibits the inflammatory reaction." The Kiel biochemists were able to support the international research team with their knowledge of IL-6 in particular. According to Grtzinger, "We have dedicated ourselves to this topic for over 20 years". Professor Stefan Rose-John added: "We hope that these fundamental findings will one day be able to aid the healing of chronic inflammatory diseases".

The Christian-Albrechts-Universitt zu Kiel (CAU) has proven international expertise as a North German research university in the field of Life Sciences. This fact is emphasised by the cluster of excellence Inflammation at Interfaces, with which the CAU was successful in the first round of the national Excellence Initiative, together with the University of Lbeck and the Research Center Borstel. The Collaborative Research Centre (CRC) 877, "Proteolysis as a Regulatory Event in Pathophysiology", whose spokesperson is Rose-John and in which Grtzinger is also involved, substantiates the competence of Kiel in the field of Life Sciences as well. CRC 877 deals with signalling pathways within and between cells, which are triggered by the fission of proteins.


'/>"/>

Contact: Dr. Joachim Groetzinger
jgroetzinger@biochem.uni-kiel.de
49-431-880-1686
Kiel University
Source:Eurekalert

Related biology news :

1. Chemical equator discovery will aid pollution mapping
2. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
3. Groundbreaking discovery may lead to stronger antibiotics
4. Discovery of natural compounds that could slow blood vessel growth
5. Nanoscopic screening process to speed drug discovery
6. FSU researchers discovery leads to $1.5 million grant, potential new treatment of liver fibrosis
7. New $11 million center to speed production of new compounds for drug discovery
8. Discovery of giant roaming deep sea protist provides new perspective on animal evolution
9. New discovery may enhance MRI scans, lead to portable MRI machines
10. Kidney function discovery sheds light on genetic complexity of disease
11. Discovery of new gene associated with diabetes risk suggests link with body clock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... MedNet,s significant achievements are the result of the company,s ... iMedNet eClinical , it,s comprehensive, easy-to-use and ... --> Key MedNet growth achievements in ...
(Date:1/18/2016)... Jan. 18, 2016  Extenua Inc., a pioneering ... the use and access of ubiquitous on-premise and ... with American Cyber.  ... leading transformational C4ISR and Cyber initiatives in support ... latest proven technology solutions," said Steve Visconti ...
(Date:1/13/2016)... ALBANY, New York , January 13, 2016 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2023. According to ... mn in 2014 and is anticipated to reach US$1,625.8 ... from 2015 to 2023. In terms of volume, the ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... BEACH, Florida , February 11, 2016 /PRNewswire/ ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), ... diagnostics, announced today that its Thermomedics subsidiary, which ... progress on its growth plan in January 2016, ... products distributors, increasing sequential monthly sales growth, and ...
(Date:2/10/2016)... , Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. (NYSE: ... pleased to announce that Mitsui & Co. Ltd., its ... succinic acid plant, is investing an additional CDN$25 million ... increasing its stake from 30% to 40%.  Mitsui will ... bio-succinic acid produced in Sarnia , ...
(Date:2/10/2016)... , ... February 10, 2016 ... ... today announced that it has joined the Human Vaccines Project, a public-private ... diseases and cancer. , The Human Vaccines Project brings together leading ...
(Date:2/10/2016)... Springfield, MO (PRWEB) , ... February 10, 2016 ... ... company, will attend the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter ... of ISPE is expecting to fill more than 100 tables for its annual ...
Breaking Biology Technology: